NewAmsterdam Pharma Company N.V. Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for NAMS, updated each market day.
NAMS AI Sentiment
AI sees no strong directional signal for NewAmsterdam Pharma Company N.V. Ordinary Shares stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Sector
Exchange
Market Cap
$4,032,188,049
Cap Tier
Employees
100
Headquarters
NARRDEN, P7
Listed Since
Nov. 23, 2022
NAMS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
NAMS Volatility
NewAmsterdam Pharma Company N.V. Ordinary Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
